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Abstract: Human papilloma virus (HPV) infection of the uterine cervix is linked to the pathogenesis of cervical 
cancer. Preclinical in vitro and in vivo studies using HPV-containing human cervical carcinoma cell lines have 
shown that the mammalian target of rapamycin (mTOR) inhibitor, rapamycin, and epidermal growth factor 
receptor (EGFR)-tyrosine kinase inhibitor, erlotinib, can induce growth delay of xenografts. Activation of Akt and 
mTOR are also observed in cervical squamous cell carcinoma and, the expression of phosphorylated mTOR was 
reported to serve as a marker to predict response to chemotherapy and survival of cervical cancer patients.  
Therefore, we investigated: a) the expression level of EGFR in cervical squamous cell carcinoma (SCC) and high-
grade squamous intraepithelial lesions (HSIL) versus non-neoplastic cervical squamous epithelium; b) the state of 
activation of the mTOR pathway in these same tissues; and c) any impact of these signal transduction molecules 
on cell cycle. Formalin-fixed paraffin-embedded tissue microarray blocks containing 20 samples each of normal 
cervix, HSIL and invasive SCC, derived from a total of 60 cases of cervical biopsies and cervical conizations were 
examined. Immunohistochemistry was utilized to detect the following antigens: EGFR; mTOR pathway markers, 
phosphorylated (p)-mTOR (Ser2448) and p-p70S6K (Thr389); and cell cycle associated proteins, Ki-67 and S 
phase kinase-associated protein (Skp)2. Protein compartmentalization and expression were quantified in regard 
to proportion (0-100%) and intensity (0-3+). Mitotic index (MI) was also assessed. An expression index (EI) for p-
mTOR, p-p70S6K and EGFR, respectively was calculated by taking the product of intensity score and proportion of 
positively staining cells. We found that plasmalemmal EGFR expression was limited to the basal/parabasal cells 
(2-3+, EI = 67) in normal cervical epithelium (NL), but was diffusely positive in all HSIL (EI = 237) and SCC (EI 
226). The pattern of cytoplasmic p-mTOR and nuclear p-p70S6K expression was similar to that of EGFR; all 
showed a significantly increased EI in HSIL/SCC versus NL (p<0.02). Nuclear translocation of p-mTOR was 
observed in all SCC lesions (EI = 202) and was significantly increased versus both HSIL (EI = 89) and NL (EI = 54) 
with p<0.015 and p<0.0001, respectively. Concomitant increases in MI and proportion of nuclear Ki-67 and Skp2 
expression were noted in HSIL and SCC. In conclusion, morphoproteomic analysis reveals constitutive activation 
and overexpression of the mTOR pathway in HSIL and SCC as evidenced by: increased nuclear translocation of p-
mTOR and p-p70S6K, phosphorylated at putative sites of activation, Ser2448 and Thr389, respectively; 
correlative overexpression of the upstream signal transducer, EGFR, and increases in cell cycle correlates, Skp2 
and mitotic indices. These results suggest that the mTOR pathway plays a key role in cervical carcinogenesis and 
targeted therapies may be developed for SCC as well as its precursor lesion, HSIL. 
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Introduction 
 
Squamous cell carcinoma (SCC) of the uterine 
cervix is the most common malignant tumor of 
the female genital tract worldwide [1]. It is well 
known that the human papilloma virus (HPV), 
especially the high risk variants HPV 16 and 
18, is the single most important etiologic 
agent in the pathogenesis of cervical 
carcinoma [1]. HPV-encoded oncoproteins, E5, 
E6 and E7 all possess immortalizing activity 
via their respective direct or indirect 
interactions with epidermal growth factor 
receptor (EGFR), p53 and retinoblastoma (Rb) 
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proteins. Past studies have shown that the 
expression of E7 is directly linked to the 
growth and survival of the HPV-associated 
cancer cells [2-5]. Furthermore, studies based 
on cell culture have also shown that the 
cellular translation machinery, namely the 
downstream effector of the mammalian target 
of rapamycin (mTOR) pathway, eukaryotic 
initiation factor (eIF) 4E via mTOR’s interaction 
with translation inhibitor 4E-BP1, plays a 
significant role in maintaining a high level of 
E7 protein expression [6]. Additionally, E5 is 
shown to activate EGFR and delay its 
degradation to promote cellular proliferation 
[7]. 
 
The serine/threonine kinase mTOR pathway is 
an appealing therapeutic target because it has 
an identified inhibitor, rapamycin, an analogue 
of which (temsirolimus) has been utilized in 
phase II and III clinical trials for metastatic 
renal cell carcinoma [8, 9]. The mTOR pathway 
has been shown in preclinical studies to play a 
role in the carcinogenesis of breast, ovary and 
prostate as well as gastrointestinal 
malignancies. Studies have also demonstrated 
that the phosphorylative activation of p70S6K 
via the mTOR pathway resulted in increased 
G1 cell cycle progression, cell survival, and 
tumor cell proliferation [10-12]. A study from 
Japan showed that Akt and mTOR are 
activated in advanced stage of cervical 
squamous cell carcinoma and the activation 
was observed to serve as a marker to predict 
response to chemotherapy and survival of 
cervical cancer patients [13]. The receptor 
tyrosine kinase (RTK), epidermal growth factor 
receptor (EGFR) is involved in the regulation of 
cell proliferation, survival, mobility, and 
differentiation [14,15]. Its expression in a 
majority of cervical SCCs and encouraging 
results from preclinical trials in various tumors 
of the lung, pancreas, central nervous system 
and head and neck has made it an attractive 
target for targeted therapy using EGFR 
inhibitors, such as erlotinib, which also show 
synergistic response with the mTOR pathway 
inhibitors, rapamycin and temsirolimus [14-
24]. 
 
The goal of this study is to characterize the 
expression levels of EGFR, the activation of the 
mTOR pathway and the proliferative cell cycle 
markers in the same tissues of cervical SCC 
and high-grade squamous intraepithelial 
lesions (HSIL) versus non-neoplastic cervical 
squamous epithelium. 
Materials and Methods 
 
Study Group 
 
The pathology database at Lyndon B. Johnson 
Hospital was retrospectively reviewed and a 
total of 60 cases of normal cervix, HSIL or 
cervical dysplasia and invasive cervical SCC 
with adequate tissue were selected with IRB 
approval. All identifiers were removed to 
protect patient’s confidentiality. Three tissue 
microarray blocks containing 20 tissue 
samples each of normal cervix, HSIL and 
invasive cervical SCC were created by 
manually re-embedding archived paraffin-
embedded tissues. 
 
Immunohistochemical Staining 
 
Tissue microarray sections, 4 μm thick, were 
deparaffinized in xylene and rehydrated in a 
graded series of ethanols. Heat-induced 
epitope retrieval was performed. Phospho-
specific probes include antibodies directed 
against mTOR and p70S6K, phosphorylated at 
putative sites of activation, serine (Ser) 2448 
and threonine (Thr) 389, respectively (Cell 
Signaling Technology, Inc., Beverly, MA, U.S.A.). 
The tissue was then treated with 3% H2O2 and 
rinsed with Tween-20 (TBST) buffer. A few 
drops of diluted normal blocking serum were 
placed on the tissue and incubated at room 
temperature. The serum was then blotted off 
and the slides were incubated with primary 
antibody overnight at 4ºC. The rest of the 
staining procedure took place on a DAKO 
Autostainer programmed to treat each slide 
with diluted biotinylated secondary antibody 
for 30 minutes. The slides were then rinsed 
and incubated with DAB (3, 3’-diamino-
benzidine chromogen solution, EnVision+ 
System Kit, DAKO) for 10 minutes. The slides 
were rinsed again and counterstained with Gill 
II hematoxylin, treated with xylene and cover 
slipped. The remaining immunohistochemical 
staining for EGFR (monoclonal, 1:50, 30 
minute incubation at room temperature, 28-
8005, Zymed, San Francisco, CA, U.S.A.), Ki-67 
(1:500, 30 minute incubation at room 
temperature, M7240, DAKO, Denmark) and 
Skp2 (1:50, 45 minute incubation at room 
temperature, sc-7164, Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA, U.S.A.) 
were performed as described above with 
DAKO Autostainer. Positive and negative 
controls were noted to react appropriately. 
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Figure 1 Representative hematoxylin-eosin (H&E) images of uterine cervical mucosa illustrating non-neoplastic 
(normal) squamous epithelium (frame A), high grade squamous intraepithelial lesion (HSIL; frame B) and invasive 
cervical squamous cell carcinoma (SCC, frame C).  Companion images depicting the level of expression of 
epidermal growth factor receptor (EGFR) on the plasmalemmal (cell membranous) aspect of the epithelial cells 
reveal: moderate to strong (2 to 3 +) DAB [brown] chromogenic signal limited to the basal and parabasal cells of 
normal epithelium (frame D); and overexpression of EGFR protein in HSIL and SCC evident by strong (3+) 
plasmalemmal expression that decorates virtually all lesional cells (frames E and F, respectively) (DAB [brown] 
chromogen; original magnification x200). 
 
 
  Table 1 Average expression index (EI) of EGFR and mTOR pathway markers: p-mTOR & p-p70S6K;   
  percent cells with positive expression of proliferation markers: Ki-67 & Skp-2; and average mitotic  
  index per ten (10) high power fields. 
Tissue 
type 
Cytoplasmi
c p-mTOR 
Nuclear 
p-mTOR 
Nuclear 
p-p70S6K 
Cytoplasmic/ 
membranous EGFR 
Mitotic 
index 
Ki-67 Skp-2 
Normal 42 54 197 67* 0 2%* 4%* 
HSIL 123 89 251 237 13 70% 25% 
SCC 94 202 251 226 14 72% 54% 
*Basal/parabasal cell staining only. Each tissue type consists of 20 specimens 
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Figure 2 Relative expression levels for mTOR pathway components, mTOR (phosphorylated on serine 2448) and 
p70S6K (phosphorylated on threonine 389) reveal: weak to moderate (1-2+) cytoplasmic and nuclear 
immunoreactivity (brown [DAB] chromogenic signal) for p-mTOR (Ser 2448) in the normal cervical squamous 
epithelium, particularly in the basal and parabasal cells (frame A) but with moderate to strong (2-3+) cytoplasmic 
and nuclear expression of this analyte in both HSIL and invasive squamous cell carcinoma involving virtually all of 
the lesional cells (frames B and C, respectively); and with diffuse and qualitatively similar nuclear expression 
levels for p-p70S6K (Thr 389) in normal cervical squamous epithelium, HSIL and invasive squamous cell 
carcinoma (frames D, E and F respectively; also see quantitative Expression Index [EI] for each of these analytes 
in Figure 4 and statistical differences in Table 2. Note the moderate cytoplasmic signal for p-p70S6K in supra 
basal zones of normal cervical epithelium (frame D) vis-à-vis that seen in HSIL and invasive squamous cell 
carcinoma (frames E and F). Subepithelial and interstitial inflammatory cell infiltrate present in HSIL and invasive 
squamous cell carcinoma shows variable nuclear signals for p-mTOR (frames B and C) and p-p70S6K (frames E 
and F) (original magnification x200). 
 
 
Tissue Microarray Analysis 
 
Two pathologists visually read the tissue array 
under the microscope and scored each core 
individually. Cases in which no epithelial cells 
were found or no core was available were 
excluded. Protein expression was 
semiquantified in regard to the intensity of cell 
staining graded as 0 to 3+ (“0” for negative 
staining if there is total absence; score of “1”, 
“2”, or “3” in order of ascending strength of 
positive staining), as well as the percentage 
(ranging from 0 to 100%) of lesion with 
positive staining of any intensity ranging from 
Feng W et al/Morphoproteomics of mTOR Pathway in Squamous Cervical Neoplasm 
1 to 3. Resulting staining intensity scores and 
percentage of positive staining were averaged 
between the two pathologists. Mitotic index 
(MI) was also assessed on routine H&E stained 
microarray slides as number of mitotic figures 
per ten (10) high power fields. An expression 
index (EI) for p-mTOR, p-p70S6K and EGFR, 
respectively was calculated by taking the 
product of intensity score and proportion of 
positively staining cells. 
 
Statistical Analysis 
 
Student t-test was used to determine 
significance of differences in staining 
expression between normal cervix, HSIL and 
SCC. Excel was used for statistical analysis 
and 2-tailed p values were used to assess 
statistical significance. 
 
Results 
 
Plasmalemmal (membranous) EGFR 
expression was strongly positive (2-3+) in the 
majority (65%) of the normal cervical 
epithelium (NL) cases but is partial and limited 
to the basal/parabasal cells with an EI of 67, 
and more diffusely and strongly positive in all 
HSIL (2-3+ in 95% of cases, EI = 237) and SCC 
(2-3+ in 90% of cases, EI 226) (Figures 1 and 
4 and Table 1). 
 
The pattern of cytoplasmic p-mTOR and 
nuclear p-p70S6K expression was similar to 
that of EGFR. Cytoplasmic p-mTOR expression 
was intermediate positive (1-2+) in most 
(100% of cases) of NL cervical epithelium but 
is partial and limited to the basal/parabasal 
cells with an EI of 67, and more diffusely and 
strongly positive in all HSIL (2-3+ in 95% of 
cases, EI = 237) and SCC (2-3+ in 90% of 
cases, EI 226). Nuclear p-p70S6K expression 
was strongly positive (2-3+) in majority (80% of 
cases) of NL cervical epithelium but was 
partial and generally limited to the basal half 
with an EI of 197, and more diffusely and 
strongly positive in all HSIL (2-3+ in 85% of 
cases, EI = 251) and SCC (2-3+ in 80% of 
cases, EI = 251) (Figures 2 and 4 and Table 
1). Moderately increased cytoplasmic retention 
of p-p70SbK was evident in the NL epithelium 
Vis-a-Vis that in HSIL/SCC. 
 
Nuclear p-mTOR expression was intermediate 
positive (1-2+) in most (95%) of NL cervical 
epithelium but is partial and limited to the 
basal/parabasal cells with an EI of 54, and 
more diffusely and strongly positive in all HSIL 
(2-3+ in 30% of cases, EI = 89) and SCC (2-3+ 
in 45% of cases, EI = 202) (Figures 2 and 4 
and Table 1). 
 
The proliferation markers Ki-67 and Skp-2 
showed similar stepwise increase in percent of 
positive cells as in the average mitotic index in 
NL cervical epithelium (limited to the 
basal/parabasal layer), HSIL (lower two-thirds 
in majority of cases) and SCC (diffuse). Skp2 
showed positive staining in a smaller percent 
of cells compared to Ki-67 in NL, HSIL and SCC 
(Figure 3 and Table 1). 
 
Cytoplasmic/plasmalemmal or membranous 
EGFR, cytoplasmic p-mTOR and nuclear p-
p70S6K all show significantly increased EI in 
HSIL/SCC compared to NL (p<0.02). The 
nuclear p-mTOR EI in SCC lesions was 
significantly increased compared to both HSIL 
and NL (p<0.015 and p<0.0001, respectively). 
Similarly, the proliferation markers Ki-67, Skp2 
and mitotic index were significantly increased 
in HSIL and SCC compared to NL (Table 2). 
 
These comparative results for normal cervical 
epithelium (NL), HSIL and SCC are graphically 
depicted in Figure 4 and Table 1, and 
significant mean differences are summarized 
in Table 2. 
 
Discussion 
 
This is a morphoproteomic study of the mTOR 
pathway in HSIL and invasive cervical SCC in 
relation to non-neoplastic (normal) uterine 
cervical epithelium. Morphoproteomic analysis 
utilizes phosphospecific probes directed 
against putative sites of activation in a given 
protein to characterize its expression level and 
subcellular translocation within a signal 
transduction pathway. It also incorporates 
expression levels of other protein analytes 
such as upstream transducers and 
downstream effectors from a signal 
transduction pathway to affirm the state of 
constitutive activation. Ultimately, comparative 
quantitation of signaling pathway activation 
between normal and neoplastic or non-
neoplastic diseased tissues provides insight 
into the potential role of a signaling pathway in 
the etiopathogenesis of a disease process 
and/or the histogenesis of a tumor [25]. 
 
The morphoproteomic analysis in this study 
reveals the constitutive activation and 
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Figure 3 Analysis of nuclear expression levels for cell cycle–associated markers, Ki-67 (G1, S, G2 and M phases 
of cell cycle) and Skp2 (S phase kinase-associated protein) reveals limited (parabasal only) expressions for both 
analytes in normal cervical squamous epithelium (frames A and B, respectively) but with strong and frequent 
expression involving middle to full thickness epithelium in HSIL and strong and diffuse expressions in invasive 
squamous cell carcinoma (frames B and D, and E and F for Ki-67 and Skp2, respectively) (original magnification x 
200; also see numerical data and statistical comparisons in Tables 1 and 2). 
 
 
overexpression of the mTOR pathway in HSIL 
and invasive cervical SCC vis-à-vis non- 
neoplastic (normal) uterine cervical epithelium 
by virtue of the following findings: the 
phosphorylation of mTOR at serine 2448 with 
nuclear translocation [25-29] and an 
increased EI in both HSIL and invasive SCC for 
cytoplasmic and nuclear p-mTOR (Ser 2448) 
as compared with normal cervical squamous 
epithelium; the correlative downstream 
overexpression of nuclear p-p70S6K (Thr 389) 
[27, 28, 30-36]; consistent cell cycle 
promoting effects of p-p70S6K in terms of the 
percent of neoplastic epithelial nuclei 
expressing the cell cycle protein analytes, Ki-
67 and Skp2 [11, 12, 37-41], as well as 
increased mitotic activity compared with the 
normal epithelial cells; and finally, correlative 
overexpression of EGFR, an upstream tyrosine 
kinase that transduces signals through both 
the PI3'-K/Akt/mTOR and ras/Raf 
kinase/extracellular signal-regulated kinase 
(ERK) 1/2 pathways, thereby contributing to 
the constitutive activation of mTOR kinase and 
p70S6K in HSIL and invasive SCC (see Figure 
5). Parenthetically, signaling of EGFR through 
both pathways is consistent with the finding by 
Bertelsen and colleagues that there is 
frequent PI3KCA amplification and Akt 
phosphorylation in uterine cervical neoplasia 
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Figure 4 Graphic representation of expression index (EI) for EGFR and mTOR pathway markers, p-mTOR (Ser 
2448) and p-p70S6K (Thr 389) comparing and contrasting normal (uterine cervical squamous epithelium), HSIL 
and invasive SCC. EI is the product of staining intensity (0-3+) and percent of positive staining cells (0-100%). C, 
cytoplasmic; N, nuclear; C/P, cytoplasmic/plasmalemmal (membranous). 
 
 
[42] and with the finding by Chen and 
associates of increased expression of 
phospho-ERK1/2 and Skp2 during tumor 
progression of cervical neoplasms [43].  
 
Moreover, these morphoproteomic findings 
coincide with the effects of HPV, the principal 
etiologic agent associated with HSIL and 
invasive SCC of the cervix, in providing an 
etiopathogenic sequence that enables the 
renewal and proliferation of the dysplastic 
process and the maintenance of growth of the 
 
 
  Table 2  Statistically significant differences among morphoproteomic analytes expression in normal   
  cervical squamous epithelium (NL), HSIL and SCC 
Significant mean differences Student’s t-test, 2 tailed p-value 
Nuclear p-mTOR in HSIL vs NL 0.049 
Nuclear p-mTOR in SCC vs NL <0.0001 
Nuclear p-mTOR in SCC vs HSIL 0.015 
Cytoplasmic p-mTOR in HSIL vs NL 0.0001 
Cytoplasmic p-mTOR in SCC vs NL 0.0026 
Nuclear p-p70S6K in HSIL vs NL 0.019 
Nuclear p-p70S6K in SCC vs NL 0.0042 
Cytoplasmic/membranous EGFR in HSIL/SCC vs NL <0.0001 
Nuclear Ki-67 in HSIL/SCC vs NL <0.0001 
Nuclear Skp2 in SCC vs NL <0.0001 
Nuclear Skp2 in SCC vs HSIL <0.0001 
Mitotic Index in HSIL/SCC vs NL <0.0001 
Mitotic Index in NL vs SCC  0.0003 
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Figure 5 A schematic composite of the complex protein circuitries identified by the authors and others utilizing 
immunohistochemistry in cases of HSIL and/or invasive squamous cell carcinoma of the uterine cervix [42, 43, 
48] and depicting established interrelationships with both HPV-encoded oncoproteins - E5, E6, and E7 [2-5, 7, 45, 
46] and with the mTOR pathway. HPV infection of cervical squamous epithelium leads to the incorporation of HPV-
oncogenes, E5, E6 and E7 into the genome resulting in the production of the corresponding oncoproteins. E5 
activates EGFR and delays its degradation resulting in increased EGFR expression and then its signaling through 
the PI3'-K/Akt and ras/Raf kinase/ERK pathway, thereby contributing to phosphorylative activation of Akt and 
ERK1/2, respectively. This accounts for the expression of p-Akt and p-ERK1/2 in HSIL and invasive squamous cell 
carcinoma. Downstream signaling by p-Akt results in the constitutive activation and expression of p-mTOR (Ser 
2448). Interaction of E6 oncoprotein with TSC2 (tuberin) contributes to signaling through the mTOR and probably 
ERK pathways [43, 45, 49, 50]. The former accounts for increased expression of p-p70S6K (Thr 389) and its 
downstream effector p-pS6 kinase and the latter collaborates with p-mTOR and contributes to activation of eIF4E 
through the phosphorylative inactivation of 4E-BP1. Additionally, p-ERK1/2 could contribute to mTOR pathway 
signaling by also contributing to the inactivation of TSC2 [51]. Translational synthesis of proteins including E7 
oncoprotein results from the activation of eIF4E. E7 oncoprotein has been linked to growth and survival 
(immortalization) of HPV-associated, transformed cancer cells and to the signaling via the Akt/mTOR pathway by 
upregulating Akt activity. Cell cycle progression associated with mTOR and ERK pathway downstream signaling 
and aided by destabilization of wild type p53 by E6 oncoprotein is consistent with the increased expressions of Ki-
67 and S phase kinase-associated protein (Skp) 2 and mitotic indices in HSIL and invasive squamous cell 
carcinoma. * indicates established immunohistochemical findings with respect to protein analytes; HSIL: high 
grade squamous intraepithelial lesion; HPV, human papilloma virus; mTOR, mammalian target of rapamycin; 
EGFR, epidermal growth factor receptor; PI3’-K, phosphatidylinositol 3-kinase; ERK, extracellular signal-regulated 
kinase; eIF4E, eukaryotic initiation factor 4E; 4E-BP1, 4E-binding protein-1. 
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invasive SCC, when it develops. Specifically, 
HPV has been implicated in high risk cervical 
cancers as well as its precursor lesion, HSIL, 
reportedly accounting for some 80% of cervical 
cancers [1, 44]. Furthermore, as noted 
previously, the HPV-encoded oncoproteins, E5, 
E6 and especially, E7 confer replicative and 
immortalizing activities in cervical neoplasms. 
Such effects are achieved, in part, by virtue of 
their interactions with or impact upon EGFR, 
TSC2, p53 and Rb proteins, respectively [2-5, 
7, 45, 46]. E5 activates EGFR and delays its 
degradation [7] and E6 interacts with and 
degrades the mTOR pathway inhibitor, 
tuberous sclerosis complex (TSC) 2 [45]. 
These effects, in turn, would lead to increased 
signaling through the PI3'-K/Akt/mTOR and 
ras/Raf kinase/ERK 1/2 pathways [25], 
eventuating in cellular proliferation. The 
binding of E6 with p53 has been shown to 
destabilize wild type p53 [5], which should 
also facilitate cell cycle progression (see Figure 
5). Similarly, the binding of viral oncoprotein, 
E7 to Rb has been linked to its transforming 
capacity [5], possibly related in part to its 
upregulation of Akt activity [46]. This sequence 
accords with our morphoproteomic findings of 
increased plasmalemmal expression of EGFR 
in HSIL and invasive SCC of the uterine cervix 
and with the correspondingly increased cell 
cycle activity, as described above. In addition, 
the constitutive activation and overexpression 
of the mTOR pathway in HSIL and invasive SCC 
in this study should result in the 
phosphorylative inactivation of 4E-BP1 and 
thereby, the release of eIF-4E to effect 
translational synthesis of proteins to include 
viral oncoprotein E7 from their corresponding 
messenger RNA [6]. As noted earlier, E7 
oncoprotein has been directly linked to the 
growth and survival (immortalization) of the 
HPV-associated cancer cells [2-5]. A schematic 
depicting the role of the HPV-encoded 
oncoproteins and incorporating our 
observations and those of others from the 
literature regarding EGFR overexpression and 
the activation and overexpression of the mTOR 
pathway with cell cycle correlates in HSIL and 
invasive cervical squamous cell carcinoma is 
represented in Figure 5. 
 
In summary, our morphoproteomic analysis of 
high grade squamous intraepithelial lesions 
and invasive squamous cell carcinoma of the 
uterine cervix strongly suggests that a 
constitutively activated and overexpressed 
mTOR pathway, acting in concert with 
overexpressed EGFR and in collaboration with 
viral oncoproteins, plays a key role in both 
neoplastic processes. Furthermore in those 
cases associated with HPV infection, which 
represent the historical majority, the mTOR 
pathway may play a role in the translational 
synthesis of the encoded viral oncogene 
protein products, leading to the perpetuation 
of HSIL and the development of invasive SCC 
in some cases. As shown in previous studies, 
HSIL has a greater risk of persistent/recurrent 
disease after excision, and is the precursor 
lesion to invasive SCC of the uterine cervix [1, 
44, 47]. Therefore, targeting the mTOR 
pathway and EGFR signaling with small 
molecule inhibitors to include a rapamycin and 
a tyrosine kinase inhibitor such as erlotinib 
[17-25] in patients with persistent or recurrent 
HSIL may be a reasonable therapeutic 
strategy. This combinatorial approach could 
obviate recurrence and reduce the risk of 
developing invasive SCC. Such an approach is 
consistent with certain stated objectives of the 
U.S. National Cancer Institute, namely to apply 
treatments or interventions at the individual 
level that keep cancers from starting or 
progressing. 
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